Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.

Eftychia ChatziioannouUlrike LeiterIoannis ThomasUlrike KeimOlivia SeeberAndreas MeiwesIsabell BoesseneckerStephanie Sanchez GonzalezFrancisco Merraz TorresHeike NiessnerTobias SinnbergAndrea ForschnerLukas FlatzTeresa Amaral

Published in: American journal of clinical dermatology (2023)

Response, according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, is, until now, the most important prognostic factor, and CR is a valid surrogate marker for long-term survival in patients treated with ICI. Our results highlight the importance of investigating the optimal therapy duration in complete responders.

Keyphrases

prognostic factors
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
cell therapy
patient reported